Clinical Trials, Recombinant Antibody and Trials

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Clinical Trials

Recombinant Antibody

Trials

Grifols’ Innovation Strategy in the Plasma Medicine Space

XTalks

DECEMBER 12, 2023

Our pipeline, for example, includes a new class of recombinant antibodies. Within the next few months we’re expecting topline results from a Phase III clinical trial on a next-generation fibrinogen, an important plasma protein essential for blood clotting. What are key pipeline initiatives for Grifols in the coming years?

Medicine

Medicine Recombinant Antibody Protein Antibody

Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors

The Pharma Data

JANUARY 18, 2021

The first patient is expected to be enrolled in this trial in the upcoming weeks. oncolytic virus (VVcopTK-RR-), and has been engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s proprietary n-CoDeR®/F.I.R.S.T IN FRANCE, FOUR CLINICAL CENTERS WILL ENROLL PATIENTS. “

Trials

Trials Antibody Engineer Clinical Trials

Clinical Research Informer

Grifols’ Innovation Strategy in the Plasma Medicine Space

Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors

Stay Connected